启新可

Search documents
齐鲁制药牵手国家自然科学基金,9900万元助力医药创新
Di Yi Cai Jing· 2025-07-07 08:59
Group 1 - The collaboration between Qilu Pharmaceutical and the National Natural Science Foundation of China (NSFC) involves the establishment of a joint fund of 99 million yuan to address challenges in the pharmaceutical industry [1][5] - The NSFC aims to promote the development of the national innovation system through partnerships with enterprises, emphasizing the importance of foundational research for subsequent industrial breakthroughs [3][5] - Qilu Pharmaceutical will contribute 30 million yuan annually for three years, totaling 90 million yuan, while the NSFC will match with 3 million yuan per year, amounting to 9 million yuan over the same period [5] Group 2 - The partnership will focus on five key areas: immune disorders, abnormal cell proliferation, gene mutations, metabolic disorders, and neurological diseases, supporting young scientists in their research [5][7] - Qilu Pharmaceutical has a strong track record in innovation, with over 320 products launched and 80 innovative drug projects currently in development, ranking third in the China Pharmaceutical Industry Top 100 [7][9] - The company has established six R&D platforms and employs a dedicated team of 5,000, with R&D investment accounting for 12% of sales revenue, totaling over 20 billion yuan during the 14th Five-Year Plan period [7][9] Group 3 - Qilu Pharmaceutical has over 80 national class I innovative drug projects, with more than 20 in clinical trials, including notable drugs for lung cancer and a global first combination antibody drug [9] - The company aims to leverage this collaboration to enhance the management of funds, organization, and projects, transitioning the biopharmaceutical industry from a follower to a leader [9]